Taken together, in the absence of SH2D2A, TCR-transgenic mice are better protected from transplanted myeloma, which correlates with reduced central deletion of tumor-specific SP CD4+ thymocytes in tumor-free mice. Here, SH2D2A is linked to neoplasm.